Curb Your Enthusiasm: Chinese Pharmas Going Global Hit Speed Bumps
Ambitious and confident Chinese pharmaceutical buyers have begun to enter a new brave world of foreign M&A. However, this scenario can be littered with internal challenges and increasingly external scrutiny, less solid pre-deal asset identification and poor post-deal execution, all of which can damage their barely gained credibility, creating hurdles for future deals.
You may also be interested in...
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
The successful IPO of China's drug innovation darling Betta may herald a new wave of capital inflow and renewed interest in new drug R&D in China, but hurdles to the pursuit of original research remain.
A new report on China’s pharma innovation ecosystem paints a grim picture of negative market returns for many novel drugs despite shortened review timelines and government calls to encourage innovation.